RESEARCH PAPER

Microfluidics in Point-of-Care Diagnostic Devices Revolutionizing Disease Detection and Management

Dr. Vamseedhar Annam[1], Dr. Abhishek. M. G.[2]*, Dr. Varaprasad. B. M [3], Dr. Anil. J[4]

.

[1]*Professor, Department of Pathology, Sapthagiri Institute of Medical Sciences and Research Center, Bangalore – 560090.*
[2]*Professor, Department of Pathology, Adichunchanagiri Institute of Medical Sciences, Adichunchanagiri University, BC Nagara, Mandya – 571448.*
[3]*Associate Professor, Department of Pathology, BGS Medical College and Hospital, Adichunchanagiri University, Nagarur, Bangalore – 562123.*
[4]*Associate Professor, Department of Pathology, BGS Medical College and Hospital, Adichunchanagiri University, Nagarur, Bangalore – 562123.*

Received: 14th Dec, 2025; Revised: 9th Feb 2026; Accepted: 11th Feb, 2026; Available Online: 28th Feb, 2026

ABSTRACT

Microfluidics has emerged as a disruptive platform in the advancement of point-of-care (POC) diagnostic technologies, enabling rapid, sensitive, and decentralized disease detection. By precisely manipulating fluids at the microscale, microfluidic systems facilitate enhanced reaction kinetics, reduced reagent consumption, and minimal sample requirements, thereby significantly improving analytical efficiency. The integration of multiple laboratory processes—such as sample preparation, separation, amplification, and detection—within compact lab-on-a-chip architectures has enabled the development of portable and user-friendly diagnostic devices suitable for real-time clinical applications.

Microfluidic POC platforms have demonstrated broad applicability across diverse disease domains, including infectious diseases (e.g., SARS-CoV-2, tuberculosis, and HIV), non-communicable diseases such as diabetes and cardiovascular disorders, and oncology through liquid biopsy and circulating tumor cell analysis. The incorporation of advanced biosensing modalities, including electrochemical, optical, and plasmonic detection systems, along with functional nanomaterials, has markedly enhanced sensitivity, selectivity, and multiplexing capabilities. Furthermore, emerging integration with digital health technologies, including smartphone-based interfaces and artificial intelligence-driven data analysis, is facilitating real-time diagnostics and decision support.

Despite these advancements, challenges related to device fabrication, reproducibility, standardization, and regulatory validation remain critical barriers to widespread clinical translation. Recent developments in low-cost substrates, particularly paper-based microfluidics, and scalable manufacturing techniques are addressing these limitations.

Overall, microfluidic POC diagnostics represent a paradigm shift toward personalized, accessible, and rapid healthcare delivery. Continued interdisciplinary innovation is expected to further optimize device performance and accelerate their integration into routine clinical practice, particularly in resource-constrained settings.

Keywords: Microfluidics; Point-of-Care Diagnostics; Lab-on-a-Chip; Biosensing; Nanomaterials; Liquid Biopsy; Multiplex Detection; Personalized Medicine

How to cite this article: Annam V, Abhishek MG, Varaprasad BM, Anil J, Microfluidics in Point-of-Care Diagnostic Devices Revolutionizing Disease Detection and Management..Int J Drug Deliv Technol. 2026;16(1): 345-351. DOI: 10.25258/ijddt.16.1.37

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

The increasing global burden of infectious and non-communicable diseases has underscored the critical need for rapid, reliable, and accessible diagnostic technologies (1). Early and accurate disease detection is fundamental to effective clinical decision-making, timely therapeutic intervention, and improved patient outcomes (2). However, conventional diagnostic methodologies predominantly rely on centralized laboratory systems that require sophisticated instrumentation, well-established infrastructure, and highly trained personnel. These requirements often result in prolonged turnaround times, increased operational costs, and limited accessibility, particularly in low- and middle-income regions. In such settings, delays in diagnosis can exacerbate disease transmission, complicate treatment strategies, and contribute to higher morbidity and mortality rates (3). Consequently, there is a pressing demand for decentralized diagnostic platforms that can deliver accurate results at or near the site of patient care.

Point-of-care (POC) diagnostics have emerged as a transformative approach to address these limitations by enabling on-site testing with minimal infrastructure. The evolution of POC technologies has been significantly accelerated by advancements in microfluidics, which offers a powerful framework for miniaturizing and integrating complex laboratory processes into compact, portable systems (4). Microfluidics, often described as the manipulation and control of fluids within microscale channels, leverages unique fluid dynamic properties that dominate at small length scales. These include laminar flow behavior, enhanced surface-to-volume ratios, and diffusion-controlled mass transport, which collectively enable precise fluid handling, efficient mixing, and rapid biochemical reactions (5). Such attributes not only improve analytical performance but also reduce reagent consumption and sample volume requirements, making microfluidic systems highly efficient and cost-effective.

The development of lab-on-a-chip (LOC) technology represents a significant milestone in the application of microfluidics to diagnostic science. LOC systems integrate multiple laboratory functions—including sample preparation, separation, amplification (e.g., polymerase chain reaction), and detection—onto a single microfabricated platform (6). This integration minimizes manual intervention, reduces the risk of contamination, and enhances reproducibility. Furthermore, the portability and automation of LOC devices make them particularly suitable for

**Author for Correspondence: Dr. Abhishek. M. G.*

deployment in resource-limited environments, field settings, and emergency situations. Over the past decade, microfluidic POC devices have demonstrated remarkable potential across a broad spectrum of biomedical applications, ranging from infectious disease diagnostics to chronic disease monitoring and oncology.

In the context of infectious diseases, microfluidic platforms have played a pivotal role in enabling rapid and sensitive detection of pathogens such as viruses, bacteria, and parasites. The recent COVID-19 pandemic highlighted the importance of decentralized diagnostic systems, where microfluidic-based assays facilitated rapid antigen and nucleic acid detection, thereby supporting large-scale screening and surveillance efforts (7). Similarly, microfluidic devices have been employed for the diagnosis of tuberculosis, malaria, and human immunodeficiency virus (HIV), offering improved accessibility and reduced dependence on centralized laboratories. In parallel, these platforms have shown considerable promise in the management of non-communicable diseases, including diabetes and cardiovascular disorders, through continuous monitoring of biomarkers such as glucose, cholesterol, and cardiac troponins.

In oncology, microfluidic technologies have opened new avenues for non-invasive cancer diagnostics, particularly through liquid biopsy approaches. The ability to isolate and analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes from small volumes of blood has revolutionized early cancer detection, prognosis, and treatment monitoring (8). The high sensitivity and specificity of microfluidic systems enable the detection of rare biomarkers, which is critical for early-stage diagnosis and personalized medicine.

The performance of microfluidic POC devices has been further enhanced by the integration of advanced biosensing technologies and functional nanomaterials. Nanomaterials such as gold nanoparticles, carbon nanotubes, graphene, and quantum dots have been widely utilized to improve signal transduction, increase surface area for biomolecular interactions, and enhance detection sensitivity (9). Additionally, the incorporation of diverse sensing modalities—including optical (fluorescence and colorimetric), electrochemical, and plasmonic techniques—has enabled multiplexed and highly selective detection of target analytes. The convergence of microfluidics with digital health technologies, including smartphone-based interfaces, wearable systems, and artificial intelligence (AI)-driven data analytics, has further expanded the capabilities of POC diagnostics by enabling real-time data acquisition, remote monitoring, and automated interpretation (10).

Despite these significant advancements, several challenges continue to impede the large-scale commercialization and clinical translation of microfluidic POC devices. Fabrication techniques, although evolving, often involve complex processes that can limit scalability and increase production costs (11). Material selection and device durability also play crucial roles in determining performance and reliability. Furthermore, issues related to standardization, reproducibility, and quality control remain critical concerns, particularly when transitioning from laboratory prototypes to market-ready products. Regulatory approval pathways for microfluidic devices are still evolving, requiring rigorous validation to ensure safety, efficacy, and compliance with international standards (12). Addressing these challenges necessitates interdisciplinary collaboration across fields such as engineering, materials science, biology, and clinical medicine.

In light of these considerations, the present study aims to provide a comprehensive and critical overview of microfluidics in point-of-care diagnostic devices, emphasizing their underlying principles, technological advancements, and diverse applications in disease detection and management. The paper further examines current limitations and emerging trends, highlighting future research directions that could facilitate the integration of microfluidic technologies into mainstream healthcare systems. By bridging the gap between laboratory innovation and clinical implementation, microfluidic POC diagnostics hold immense potential to revolutionize global healthcare delivery, particularly by improving diagnostic accessibility, reducing healthcare disparities, and advancing the paradigm of personalized medicine.

2. FUNDAMENTALS OF MICROFLUIDICS IN DIAGNOSTIC SYSTEMS

Microfluidics represents a multidisciplinary field that encompasses fluid mechanics, materials science, microfabrication, and analytical chemistry, focusing on the manipulation of fluids at the micrometer scale. Typically involving volumes in the range of microliters to picoliters, microfluidic systems exhibit unique physicochemical behaviors that are fundamentally different from those observed in conventional macroscale fluid systems (13). These differences arise primarily due to the dominance of surface forces, viscous effects, and interfacial phenomena over inertial forces. Such distinctive characteristics enable precise spatiotemporal control over fluid flow and biochemical reactions, thereby forming the foundation for the development of highly efficient, miniaturized diagnostic platforms for point-of-care (POC) applications.

2.1 Principles of Microfluidics

The functionality of microfluidic diagnostic systems is governed by several key physical principles that dictate fluid behavior and transport mechanisms at small scales:

Laminar Flow Regime:

Fluid flow in microchannels is characterized by low Reynolds numbers ($Re << 1$), resulting in laminar, non-turbulent flow. In this regime, fluid streams move in well-defined, parallel layers without chaotic mixing. This predictable flow behavior allows for precise control over fluid interfaces and reaction zones, which is essential for reproducible diagnostic assays. Laminar flow also facilitates the creation of stable concentration gradients, which are useful in applications such as cell analysis and biomarker detection.

Diffusion-Dominated Mass Transport:

In the absence of turbulence, mixing between fluid streams occurs primarily through molecular diffusion. At the microscale, the diffusion path length is significantly reduced, enabling rapid mixing despite the laminar flow conditions. This enhances reaction kinetics and improves the efficiency of biochemical interactions, such as antigen–antibody binding or nucleic acid hybridization. However, controlled mixing strategies—such as the incorporation of microstructures or serpentine channels—are often employed to further enhance diffusion.

Capillary Action and Passive Flow Mechanisms:

Capillary forces, arising from the interaction between liquid surface tension and solid surfaces, play a critical role in driving fluid flow in many microfluidic systems. This phenomenon is particularly exploited in paper-based microfluidics and other passive devices, where fluid transport occurs without the need for external pumps or power sources. Capillary-driven flow significantly simplifies device design and enhances portability, making it ideal for POC applications in resource-limited settings.

Surface Tension and Interfacial Effects:

At the microscale, surface tension becomes a dominant force influencing fluid behavior, including droplet formation, stability, and manipulation. Interfacial phenomena are particularly important in droplet-based and digital microfluidics, where discrete fluid volumes are controlled with high precision. Wettability, contact angle, and surface energy play crucial roles in determining fluid movement and interaction with channel surfaces.

Electrokinetic and Magnetohydrodynamic Effects (Advanced Systems):

In more advanced microfluidic platforms, external fields such as electric or magnetic fields are utilized to manipulate fluid flow and particles. Electroosmotic flow, dielectrophoresis, and magnetophoresis enable precise control over sample transport, separation, and concentration, thereby enhancing device functionality and analytical performance.

2.2 Materials and Fabrication Techniques

The choice of materials and fabrication methods is a critical determinant of the performance, cost-effectiveness, and scalability of microfluidic diagnostic devices. Materials must exhibit properties such as biocompatibility, chemical stability, optical transparency (for detection), and ease of fabrication.

Polydimethylsiloxane (PDMS):

PDMS is one of the most widely used materials in microfluidics due to its flexibility, optical transparency, gas permeability, and ease of fabrication via soft lithography. It is particularly suitable for prototyping and biological applications. However, its hydrophobic nature and potential for small molecule absorption can limit its use in certain applications.

Glass and Silicon:

These materials offer excellent mechanical strength, thermal stability, and chemical resistance. They are ideal for high-precision and high-temperature applications, such as PCR-based diagnostics. Fabrication typically involves photolithography and etching processes, which, although precise, are relatively expensive and less suitable for large-scale production.

Thermoplastics (e.g., PMMA, polycarbonate, polystyrene):

Thermoplastics are increasingly favored for commercial applications due to their low cost, durability, and compatibility with mass production techniques such as injection molding and hot embossing. These materials support scalable manufacturing and are widely used in disposable diagnostic devices.

Paper-Based Materials:

Cellulose-based substrates are extensively used in low-cost microfluidic devices (μPADs). Their inherent porosity enables passive fluid transport through capillary action, eliminating the need for external actuation. These systems are particularly advantageous for rapid, disposable diagnostics in field settings.

Emerging Materials:

Advances in materials science have introduced novel substrates such as hydrogels, flexible polymers, and nanocomposite materials, which offer enhanced functionality, including improved sensitivity, flexibility, and integration with wearable devices.

Fabrication techniques vary depending on the material and application requirements. Common methods include soft lithography**,** photolithography**,** laser micromachining**,** 3D printing, and injection molding. While soft lithography is widely used for rapid prototyping, injection molding and roll-to-roll processing are more suitable for large-scale manufacturing. The choice of fabrication technique directly impacts device resolution, reproducibility, and cost.

2.3 Types of Microfluidic Platforms

Microfluidic diagnostic devices can be broadly categorized based on their operational mechanisms and design architectures:

Lab-on-a-Chip (LOC) Systems:

LOC devices represent highly integrated platforms that consolidate multiple laboratory functions onto a single chip. These systems enable automated sample processing, including mixing, separation, amplification, and detection, thereby reducing human intervention and minimizing errors. LOC platforms are widely used in molecular diagnostics, immunoassays, and nucleic acid amplification tests due to their high precision and multiplexing capabilities.

Paper-Based Microfluidics (μPADs):

μPADs utilize patterned paper substrates to create microfluidic channels. Fluid movement is driven by capillary action, making these devices simple, low-cost, and power-free. They are particularly suitable for rapid diagnostic tests, such as lateral flow assays, and are widely used in resource-limited environments.

Digital Microfluidics (DMF):

Digital microfluidic systems manipulate discrete droplets on an array of electrodes using electrowetting-on-dielectric (EWOD) principles. This approach allows for precise control over droplet movement, merging, splitting, and mixing. DMF platforms offer high flexibility, reduced reagent consumption, and minimal cross-contamination, making them suitable for complex and programmable diagnostic assays.

Droplet-Based Microfluidics:

In this approach, discrete droplets are generated within immiscible carrier fluids, enabling high-throughput screening and single-cell analysis. This platform is particularly useful for applications requiring compartmentalization, such as enzyme kinetics and single-cell genomics.

3. DESIGN AND WORKING MECHANISMS OF MICROFLUIDIC POC DEVICES

Microfluidic point-of-care (POC) diagnostic devices are designed to integrate complex analytical processes into compact, automated platforms capable of delivering rapid and accurate results. Their performance is governed by the interplay between device architecture, fluid manipulation strategies, detection techniques, and the seamless integration of sample preparation with analytical functions. These systems aim to achieve “sample-to-answer” capability with minimal user intervention, making them highly suitable for decentralized healthcare applications.

3.1 Device Architecture and Components

The architecture of microfluidic POC devices is based on a network of microscale channels and functional modules that collectively facilitate fluid transport, reaction, and detection. Microchannels serve as the primary pathways for fluid movement and are engineered with precise geometries to regulate flow behavior and enhance mixing efficiency. Reaction chambers are incorporated within the chip to provide controlled environments for biochemical interactions, such as antigen–antibody binding or nucleic acid amplification.

In addition, microfluidic devices include inlets and outlets for sample introduction and waste removal, often supporting multiplexed analysis through multiple input streams. Flow regulation is achieved using microvalves and micropumps, which may operate through passive mechanisms or external actuation (14). Mixing units, such as serpentine channels or microstructured surfaces, are designed to overcome diffusion limitations, while separation modules enable the isolation of target analytes using size-based, inertial, or affinity-based techniques. Detection zones are strategically positioned to maximize signal acquisition and minimize interference. The modular nature of these architectures allows flexibility in design and facilitates the integration of multiple analytical steps within a single platform.

3.2 Fluid Manipulation Techniques (Passive vs Active Systems)

Fluid manipulation is a critical aspect of microfluidic device operation, determining the efficiency and reproducibility of diagnostic assays. Passive microfluidic systems rely on intrinsic forces such as capillary action, surface tension, and gravitational effects to drive fluid flow (15). These systems are particularly advantageous due to their simplicity, low cost, and independence from external power sources. Paper-based microfluidic devices and lateral flow assays exemplify passive systems, where fluid transport occurs through porous substrates via capillary forces. However, passive systems often provide limited control over flow dynamics and timing.

In contrast, active microfluidic systems utilize external energy inputs to achieve precise and programmable fluid control. Techniques such as electroosmotic flow, dielectrophoresis, magnetophoresis, and pressure-driven flow enable controlled

manipulation of fluids and suspended particles. These approaches allow for enhanced control over flow rates, mixing, and sequential processing, making them suitable for complex, multi-step diagnostic applications. Despite their advantages, active systems may introduce additional complexity, increased energy requirements, and higher fabrication costs.

3.3 Detection Methods (Optical, Electrochemical, and Biosensors)

Detection mechanisms play a pivotal role in determining the analytical performance of microfluidic POC devices. Optical detection techniques, including fluorescence, absorbance, chemiluminescence, and colorimetric assays, are widely employed due to their high sensitivity and compatibility with microfluidic platforms (16). Fluorescence-based methods are particularly effective for detecting nucleic acids and proteins at low concentrations, while colorimetric assays provide simple, cost-effective visual outputs suitable for resource-limited settings.

Electrochemical detection methods offer several advantages, including rapid response, high sensitivity, and ease of integration with miniaturized electronic systems. These methods detect changes in electrical parameters such as current, voltage, or impedance in response to biochemical interactions. Biosensors further enhance detection capabilities by incorporating biological recognition elements, such as enzymes, antibodies, or nucleic acids, coupled with physicochemical transducers. The integration of nanomaterials, including gold nanoparticles, graphene, and quantum dots, has significantly improved signal amplification and detection sensitivity. Emerging techniques, such as surface plasmon resonance and Raman spectroscopy, provide label-free and ultra-sensitive detection, further expanding the capabilities of microfluidic diagnostic systems.

3.4 Integration of Sample Preparation and Analysis

A key advancement in microfluidic POC devices is the integration of sample preparation and analytical processes into a single platform, enabling true "sample-to-answer" functionality. These systems are capable of processing raw biological samples, such as blood, saliva, or urine, by incorporating on-chip operations including filtration, cell lysis, dilution, and purification. This reduces the need for external preprocessing and minimizes the risk of contamination.

Target analytes can be selectively isolated and enriched using techniques such as immunoaffinity capture, magnetic bead separation, and size-based filtration, thereby enhancing detection sensitivity. Subsequent analytical steps, including nucleic acid amplification (e.g., PCR and isothermal amplification methods) and immunoassays, are performed within the same microfluidic environment. The integration of these processes enables automated workflows, reduces analysis time, and improves reproducibility. Such fully integrated systems are particularly valuable in point-of-care settings, where rapid and reliable diagnostics are essential for timely clinical decision-making.

4. APPLICATIONS IN DISEASE DETECTION AND MANAGEMENT

Microfluidic point-of-care (POC) diagnostic devices have emerged as versatile and transformative tools across a broad spectrum of applications in disease detection and management. Their ability to perform rapid, sensitive, and decentralized analysis using minimal sample volumes has significantly enhanced diagnostic accessibility and efficiency. By integrating microfluidic platforms with advanced biosensing technologies, these systems facilitate early diagnosis, real-time monitoring, and improved clinical decision-making, particularly in resource-constrained environments.

4.1 Infectious Diseases

Microfluidic POC technologies have demonstrated substantial impact in the detection and control of infectious diseases, where rapid diagnosis is critical for effective treatment and containment. These platforms have been widely applied for the detection of viral, bacterial, and parasitic pathogens, including SARS-CoV-2, *Mycobacterium tuberculosis*, and human immunodeficiency virus (HIV). The COVID-19 pandemic underscored the importance of decentralized diagnostics, with microfluidic-based antigen and nucleic acid amplification tests enabling rapid and large-scale screening (17). Similarly, microfluidic PCR and isothermal amplification systems have improved the sensitivity and portability of tuberculosis diagnostics compared to conventional methods. In HIV management, microfluidic devices enable point-of-care viral load quantification and CD4+ T-cell enumeration, supporting timely clinical intervention. Collectively, these systems enhance disease surveillance, reduce diagnostic delays, and contribute to improved public health outcomes.

4.2 Non-Communicable Diseases

The increasing prevalence of non-communicable diseases (NCDs), particularly diabetes and cardiovascular disorders, has driven the adoption of microfluidic POC devices for continuous and real-time health monitoring. In diabetes management, microfluidic-based glucose sensors, including wearable systems, enable continuous monitoring of blood glucose levels, thereby improving glycemic control and patient compliance (18). In cardiovascular diagnostics, microfluidic platforms facilitate the rapid detection of biomarkers such as cardiac troponins, C-reactive protein, and lipid profiles, enabling early diagnosis of acute and chronic cardiac conditions. The integration of microfluidics with digital health technologies, including smartphone-based interfaces and wearable devices, further enhances personalized disease management and remote patient monitoring.

4.3 Cancer Diagnostics

Microfluidic technologies have significantly advanced cancer diagnostics by enabling non-invasive, highly sensitive detection of tumor-derived biomarkers. Liquid biopsy, which involves the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes, has gained prominence as an alternative to conventional tissue biopsy. Microfluidic platforms offer precise fluid control and high surface-area interactions, facilitating the efficient isolation and enrichment of rare biomarkers from complex biological matrices (19). This capability is critical for early cancer detection, prognosis, and monitoring therapeutic response. Furthermore, on-chip molecular analysis enables the identification of genetic and epigenetic alterations, supporting the development of precision oncology and personalized treatment strategies.

4.4 Environmental and Food Safety Applications

In addition to biomedical applications, microfluidic POC devices have been increasingly utilized in environmental monitoring and food safety assessment. These platforms enable rapid detection of biological and chemical contaminants, including pathogenic microorganisms, toxins, heavy metals, and pesticide residues. In environmental monitoring, microfluidic systems are employed for on-site detection of waterborne pathogens and pollutants, providing real-time data for environmental risk assessment (20). In the food industry, these devices facilitate the rapid screening of foodborne pathogens such as *Escherichia coli* and *Salmonella*, ensuring food quality and safety. The incorporation of biosensors and nanomaterials enhances detection sensitivity and specificity, enabling early identification of contaminants and reducing public health risks.

5. ADVANTAGES, LIMITATIONS, AND CHALLENGES

Microfluidic point-of-care (POC) diagnostic devices have emerged as a transformative technological paradigm in modern healthcare, offering the potential to overcome many limitations associated with conventional laboratory-based diagnostics. By

enabling rapid, decentralized, and cost-effective testing, these systems address critical gaps in accessibility and timeliness of diagnosis. However, despite substantial progress in recent years, the widespread clinical translation and commercialization of microfluidic POC technologies remain constrained by a combination of technical, operational, and regulatory challenges (21). A comprehensive understanding of both the advantages and limitations of these systems is therefore essential to evaluate their current capabilities and future prospects.

5.1 Key Advantages

Microfluidic POC devices provide several distinct advantages that collectively contribute to their growing prominence in diagnostic applications. One of the most significant benefits is the rapid analytical turnaround enabled by microscale fluid dynamics. The reduced dimensions of microchannels enhance mass and heat transfer, leading to accelerated reaction kinetics and significantly shorter assay times compared to conventional methods. This rapid response is particularly critical in clinical scenarios requiring immediate decision-making, such as infectious disease outbreaks, emergency diagnostics, and critical care settings.

Another major advantage is the substantial reduction in sample and reagent consumption. Microfluidic systems operate with microliter- to nanoliter-scale volumes, thereby minimizing the use of expensive reagents and enabling cost-effective testing (22). This feature is especially valuable for large-scale screening programs and applications in resource-limited settings. Furthermore, the compact and lightweight nature of microfluidic devices enhances their portability, allowing deployment in decentralized environments such as rural healthcare facilities, field settings, and even at-home diagnostics.

The integration of advanced detection technologies, including electrochemical, optical, and nanomaterial-enhanced biosensors, significantly improves analytical sensitivity and specificity. These systems are capable of detecting low-abundance biomarkers with high precision, facilitating early disease diagnosis and monitoring. Additionally, the potential for automation and integration of multiple analytical steps into a single platform reduces human intervention, minimizes operational errors, and enhances reproducibility. The compatibility of microfluidic devices with digital technologies, such as smartphone-based readouts and cloud-based data analysis, further supports real-time diagnostics and remote healthcare delivery.

5.2 Technical and Operational Limitations

Despite their considerable advantages, microfluidic POC devices face several technical and operational challenges that limit their widespread implementation. Fabrication complexity remains a primary concern, particularly for devices requiring high-resolution microstructures, multi-layer configurations, and precise alignment of components. Conventional fabrication techniques, such as photolithography and soft lithography, while highly accurate, are often labor-intensive, costly, and not readily scalable for industrial production.

Device reliability and reproducibility also present significant challenges. Variations in fabrication processes, material inconsistencies, and surface modifications can lead to batch-to-batch variability, affecting device performance and analytical accuracy (23). Common issues encountered in microfluidic systems include channel clogging, air bubble formation, evaporation of small fluid volumes, and non-specific adsorption of biomolecules onto channel surfaces. These factors can compromise assay sensitivity and lead to erroneous results.

Moreover, the integration of multiple functional steps—such as sample preparation, target enrichment, amplification, and detection—into a single microfluidic platform remains a complex engineering challenge. Handling complex biological samples, such as whole blood or saliva, requires robust preprocessing mechanisms, including filtration, cell lysis, and purification, which must be efficiently incorporated without increasing device complexity (24). Additionally, active microfluidic systems often require external power sources, pumps, or control units, which may reduce portability and increase operational costs.

Environmental stability is another critical consideration. Variations in temperature, humidity, and storage conditions can affect reagent stability and device performance, particularly in field applications. Ensuring consistent and reliable operation under diverse environmental conditions remains a key challenge for real-world deployment.

5.3 Standardization, Scalability, and Regulatory Issues

The successful transition of microfluidic POC devices from laboratory research to commercial products is heavily dependent on addressing issues related to standardization, scalability, and regulatory compliance. Currently, the absence of universally accepted standards for device design, fabrication, and performance evaluation poses a significant barrier to clinical adoption. The lack of standardized protocols makes it difficult to compare results across different platforms and hinders the validation and benchmarking of new technologies (25). Establishing uniform guidelines for performance metrics, quality control, and validation is essential to ensure reliability and reproducibility.

Scalability remains another major challenge, as many microfluidic devices are developed using prototyping techniques that are not easily adaptable to high-volume manufacturing. While advancements in thermoplastics, injection molding, and roll-to-roll processing have improved the prospects for large-scale production, achieving consistent device quality at low cost remains difficult. Material selection, process optimization, and quality assurance are critical factors that influence scalability and commercial viability.

Regulatory approval represents a further obstacle to the widespread adoption of microfluidic POC devices. Regulatory agencies require extensive validation of device safety, efficacy, and analytical performance before granting approval for clinical use. This process often involves rigorous preclinical and clinical testing, which can be time-consuming and resource-intensive. Additionally, the rapidly evolving nature of microfluidic technologies presents challenges for regulatory frameworks that may not be fully adapted to accommodate these innovations. The development of clear and streamlined regulatory pathways, along with robust validation methodologies, is essential to facilitate market entry and adoption.

6. RECENT ADVANCES AND FUTURE PERSPECTIVES

Microfluidic point-of-care (POC) diagnostic technologies have undergone remarkable advancements over the past decade, driven by synergistic developments in nanotechnology, biosensing, materials science, and digital health. These interdisciplinary innovations have significantly improved the analytical performance, sensitivity, and functional integration of microfluidic platforms, transforming them from simple fluid-handling systems into sophisticated, multifunctional diagnostic tools. As healthcare systems increasingly shift toward decentralized, personalized, and preventive models, microfluidic POC devices are poised to play a pivotal role in enabling rapid, real-time, and data-driven disease management. The integration of emerging technologies such as artificial intelligence (AI), wearable systems, and advanced manufacturing approaches is further redefining the scope and capabilities of these platforms.

6.1 Integration with Nanotechnology and Biosensors

The convergence of microfluidics with nanotechnology has been a key driver in enhancing the sensitivity and specificity of diagnostic devices. Nanomaterials, including gold nanoparticles, silver nanoparticles, graphene, carbon nanotubes, and quantum dots, possess unique electrical, optical, and catalytic properties

that significantly improve signal transduction and amplification. Their high surface-to-volume ratios facilitate efficient immobilization of biomolecules, thereby increasing the probability of target–analyte interactions and enabling the detection of ultra-low concentrations of biomarkers.

In parallel, advancements in biosensor technology have enabled the development of highly selective and multiplexed detection systems. Immunosensors, enzymatic biosensors, aptamer-based sensors, and nucleic acid-based detection platforms have been successfully integrated into microfluidic devices to achieve rapid and accurate biomarker identification. The incorporation of nanostructured sensing interfaces has further enhanced detection limits and reduced background noise, enabling high-throughput and multi-analyte detection within a single platform. Such integration is particularly valuable for complex disease diagnostics, including cancer and infectious diseases, where simultaneous detection of multiple biomarkers is required for accurate clinical interpretation. The ongoing development of hybrid nano-bio interfaces is expected to further improve device performance and expand the range of detectable analytes.

6.2 AI and Smartphone-Based Diagnostics

The integration of artificial intelligence (AI) and smartphone-based technologies with microfluidic platforms represents a transformative advancement in POC diagnostics. AI-driven algorithms, particularly those based on machine learning and deep learning, enable automated interpretation of complex diagnostic data, including optical signals, electrochemical outputs, and imaging-based results. These systems can identify patterns, detect anomalies, and provide predictive insights, thereby enhancing diagnostic accuracy and reducing reliance on expert interpretation. Smartphones have emerged as powerful tools for interfacing with microfluidic devices due to their widespread availability, advanced imaging capabilities, and computational power. Smartphone-based diagnostic systems can capture and analyze signals from microfluidic assays, display results in real time, and transmit data to cloud-based platforms for further analysis. This integration facilitates telemedicine, remote diagnostics, and large-scale epidemiological monitoring. Moreover, the use of mobile applications enables user-friendly interfaces, guiding non-expert users through diagnostic procedures and reducing operational errors. The combination of AI and smartphone technologies is thus enabling the development of intelligent, connected diagnostic systems that are accessible, scalable, and adaptable to diverse healthcare settings.

6.3 Wearable and Real-Time Monitoring Systems

Recent progress in flexible electronics, soft materials, and microfabrication techniques has led to the development of wearable microfluidic devices capable of continuous and real-time health monitoring. These systems are designed to non-invasively analyze biofluids such as sweat, interstitial fluid, and saliva, providing dynamic insights into physiological and biochemical parameters. Wearable microfluidic platforms have been successfully applied for monitoring glucose levels, electrolyte balance, lactate concentration, and stress-related biomarkers, among others.

The integration of microfluidics with wearable sensors enables continuous data acquisition, allowing for early detection of physiological abnormalities and timely medical intervention. These devices can be seamlessly integrated with wireless communication technologies, enabling real-time data transmission to healthcare providers and cloud-based platforms. This facilitates remote patient monitoring and supports the development of personalized treatment strategies. Furthermore, wearable microfluidic systems align with the broader vision of preventive healthcare, shifting the focus from reactive treatment to proactive disease management. As these technologies continue to evolve, they are expected to play a critical role in managing chronic diseases and improving overall healthcare outcomes.

6.4 Future Research Directions and Commercialization Potential

Despite significant progress, several challenges must be addressed to fully realize the clinical and commercial potential of microfluidic POC technologies. Future research should focus on enhancing device robustness, reproducibility, and long-term stability, particularly under varying environmental conditions. The development of fully integrated "sample-to-answer" systems that combine sample preparation, target enrichment, amplification, and detection within a single platform remains a key objective.

Advancements in materials science will play a crucial role in improving device performance, with emerging materials such as hydrogels, nanocomposites, and flexible polymers offering enhanced biocompatibility, sensitivity, and mechanical properties. In parallel, the adoption of scalable manufacturing techniques—such as injection molding, roll-to-roll processing, and advanced additive manufacturing (3D printing)—is essential for transitioning from laboratory prototypes to mass-produced, cost-effective devices. Ensuring consistency and quality control during large-scale production remains a critical challenge that requires further innovation.

From a commercialization perspective, microfluidic POC devices hold significant market potential due to the increasing demand for rapid and decentralized diagnostics. Their integration with digital health ecosystems, including telemedicine platforms and electronic health records, further enhances their value proposition. However, successful commercialization will require addressing regulatory challenges, establishing standardized validation protocols, and ensuring user-centric design for ease of operation. Collaboration between academia, industry, and regulatory agencies will be essential to accelerate the translation of these technologies into clinically approved and widely adopted products.

REFERENCE

1. Whitesides, G. M. (2006). The origins and the future of microfluidics. Nature, 442(7101), 368–373. https://doi.org/10.1038/nature05058
2. Sia, S. K., & Kricka, L. J. (2008). Microfluidics and point-of-care testing. Lab on a Chip, 8(12), 1982–1983. https://doi.org/10.1039/b814086c
3. Chin, C. D., Linder, V., & Sia, S. K. (2012). Commercialization of microfluidic point-of-care diagnostic devices. Lab on a Chip, 12(12), 2118–2134. https://doi.org/10.1039/c2lc21204h
4. Yetisen, A. K., Akram, M. S., & Lowe, C. R. (2013). Paper-based microfluidic point-of-care diagnostic devices. Lab on a Chip, 13(12), 2210–2251. https://doi.org/10.1039/c3lc50169h
5. Martinez, A. W., Phillips, S. T., Whitesides, G. M., & Carrilho, E. (2010). Diagnostics for the developing world: Microfluidic paper-based analytical devices. Analytical Chemistry, 82(1), 3–10. https://doi.org/10.1021/ac9013989
6. Sackmann, E. K., Fulton, A. L., & Beebe, D. J. (2014). The present and future role of microfluidics in biomedical research. Nature, 507(7491), 181–189. https://doi.org/10.1038/nature13118
7. Zhang, Y., & Ozdemir, P. (2009). Microfluidic DNA amplification—A review. Analytica Chimica Acta, 638(2), 115–125. https://doi.org/10.1016/j.aca.2009.02.049
8. Li, X., Ballerini, D. R., & Shen, W. (2012). A perspective on paper-based microfluidics: Current status and future trends. Biomicrofluidics, 6(1), 011301. https://doi.org/10.1063/1.3687398
9. Jokerst, J. C., Emory, J. M., & Henry, C. S. (2012). Programmable microfluidics for drug discovery. Science

Translational Medicine, 4(143), 143rv5. https://doi.org/10.1126/scitranslmed.3003365
10. Nguyen, N. T., & Wereley, S. T. (2006). Fundamentals and applications of microfluidics. Artech House.
11. Yager, P., Domingo, G. J., & Gerdes, J. (2008). Point-of-care diagnostics for global health. Annual Review of Biomedical Engineering, 10, 107–144. https://doi.org/10.1146/annurev.bioeng.10.061807.160524
12. Chin, C. D., Laksanasopin, T., Cheung, Y. K., Steinmiller, D., Linder, V., Parsa, H., Wang, J., Moore, H., Rouse, R., Umviligihozo, G., Karita, E., Mwambarangwe, L., Braunstein, S. L., van de Wijgert, J., Sahabo, R., Justman, J. E., El-Sadr, W., & Sia, S. K. (2011). Microfluidics-based diagnostics of infectious diseases in the developing world. Nature Medicine, 17(8), 1015–1019. https://doi.org/10.1038/nm.2408
13. Gubala, V., Harris, L. F., Ricco, A. J., Tan, M. X., & Williams, D. E. (2012). Point of care diagnostics: Status and future. Analytical Chemistry, 84(2), 487–515. https://doi.org/10.1021/ac2030199
14. Laksanasopin, T., Guo, T. W., Nayak, S., Sridhara, A. A., Xie, S., Olowookere, O. O., Cadinu, P., Meng, F., Chee, N. H., Kim, J., Chin, C. D., Munyazesa, E., Mugwaneza, P., Rai, A. J., Mugisha, V., Castro, A. R., Steinmiller, D., Linder, V., Justman, J. E., & Sia, S. K. (2015). A smartphone dongle for diagnosis of infectious diseases at the point of care. Science Translational Medicine, 7(273), 273re1. https://doi.org/10.1126/scitranslmed.aaa0056
15. Cate, D. M., Adkins, J. A., Mettakoonpitak, J., & Henry, C. S. (2015). Recent developments in paper-based microfluidic devices. Analytical Chemistry, 87(1), 19–41. https://doi.org/10.1021/ac503968p
16. Nayak, S., & Blumenfeld, N. R. (2019). Microfluidics for personalized medicine. Annual Review of Biomedical Engineering, 21, 101–125. https://doi.org/10.1146/annurev-bioeng-060418-052348
17. Hassan, U., Ghonge, T., Reddy, B., Patel, M., Rappleye, M., Taneja, I., Taneja, T., & Bashir, R. (2017). Microfluidic-based diagnostics for infectious diseases. Lab on a Chip, 17(4), 573–601. https://doi.org/10.1039/c6lc01337k
18. Gao, D., Liu, H., Jiang, Y., Lin, J. M., & Li, X. (2017). Recent advances in microfluidic devices for cancer detection. Trends in Analytical Chemistry, 95, 63–73. https://doi.org/10.1016/j.trac.2017.07.001
19. Dittrich, P. S., & Manz, A. (2006). Lab-on-a-chip: Microfluidics in drug discovery. Nature Reviews Drug Discovery, 5(3), 210–218. https://doi.org/10.1038/nrd1985
20. Mark, D., Haeberle, S., Roth, G., von Stetten, F., & Zengerle, R. (2010). Microfluidic lab-on-a-chip platforms: Requirements, characteristics and applications. Chemical Society Reviews, 39(3), 1153–1182. https://doi.org/10.1039/b820557b
21. Yetisen, A. K., Akram, M. S., & Lowe, C. R. (2017). Nanotechnology in microfluidic biosensors. Lab on a Chip, 17(7), 1134–1144. https://doi.org/10.1039/c6lc01537a
22. Bhattacharjee, N., Urrios, A., Kang, S., & Folch, A. (2016). The upcoming 3D-printing revolution in microfluidics. Lab on a Chip, 16(10), 1720–1742. https://doi.org/10.1039/c6lc00163g
23. McDonald, J. C., & Whitesides, G. M. (2002). Poly(dimethylsiloxane) as a material for microfluidics. Accounts of Chemical Research, 35(7), 491–499. https://doi.org/10.1021/ar010110q
24. Sun, J., et al. (2020). Advances in microfluidic-based biosensors for COVID-19 detection. Biosensors and Bioelectronics, 165, 112437. https://doi.org/10.1016/j.bios.2020.112437
25. Zhang, D., et al. (2021). Microfluidic platforms for rapid detection of SARS-CoV-2. Trends in Analytical Chemistry, 138, 116229. https://doi.org/10.1016/j.trac.2021.116229.